The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant ...

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among ...

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox ...